- Abstract
- 10.1136/jitc-2024-sitc2024.1288
1288 Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6
- Nov 01, 2024
- Journal for ImmunoTherapy of Cancer
- Kelly Byrnes-Blake + 3 more +3
BackgroundCTIM-76 is a Claudin 6 (CLDN6) x CD3 bispecific T cell-redirecting antibody that is in phase 1 clinical development. The minimal anticipated biological effect level (MABEL) approach is standard for determining the first-in-human dose potent of immune-activating drugs.MethodsAccordingly, we aimed to determine the first-in-human dose of CTIM-76 using both the MABEL and no observed adverse effect level (NOAEL) approaches. CTIM-76-induced lysis of OV-90 tumor cells was determined to be the most sensitive and pharmacologically relevant measure for MABEL calculations and resulted in a starting dose of 22.5 mcg.ResultsIn the 4-week GLP toxicology study in nonhuman primates the highest non-severely toxic dose (HNSTD) was 0.2 mg/kg. Based on ICH S9 guidance, this results in a maximum recommended starting dosage (MRSD) of 0.033 mg/kg. This is substantially higher than the proposed FIH dose of 22.5 mcg (0. 32 mcg/kg). Based on the predicted human PK, a 22.5 mcg dose would give a Cmax and AUC of 5.33 ng/mL and 206 hr*ng/mL, respectively, which would provide a Cmax approximately equivalent to the EC50 value from the OV-90 assay. This minimally pharmacologically active dose level is consistent with the dose proposed by the MABEL approach. The mean (SD) Cmax and AUC values, based on males and females combined, after repeat dosing (Day 29) of the HNSTD of 0.2 mg/kg, were 2460 (820) ng/mL and 80900 (37800) hr*ng/mL, respectively. Therefore, a 22.5 mcg dose in humans would have safety margins of 462 and 393 based on Cmax and AUC, respectively.ConclusionsThe weight of evidence of these data supports the safety of the proposed clinical starting dose of 22.5 mcg CTIM-76.
Read more